Published in Medical Letter on the CDC and FDA, October 30th, 2005
Proxinium combines a powerful cytotoxic protein payload with the precise tumour-targeting characteristics of a monoclonal antibody. A single molecule of the cytotoxic protein payload, Pseudomonas exotoxin, is capable of killing a cancer cell. The antibody fragment of Proxinium targets EpCAM, an antigen that is highly expressed on many epithelial cancers including head and neck cancer, ensuring that the payload is delivered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.